Ann Arbor-based Arboretum Ventures, one of the top venture capital firms in the Midwest, has hired the former CEO of the Ann Arbor biotech firm Aastrom Biosciences. George Dunbar, who stepped down as CEO of Aastrom last month, is joining Arboretum as a venture partner. That means he'll help Arboretum, ...
Timothy Mayleben is endowed with the Esperion Therapeutics mystique. Whether that helps him rescue Ann Arbor-based biotechnology firm Aastrom Biosciences is to be determined. Mayleben, a longtime Aastrom board member, became CEO last week after ex-CEO George Dunbar asked him to take over. Dunbar will remain chairman in a transition ...
Ann Arbor-based Aastrom Biosciences is launching another Phase 2 clinical trial to study the effectiveness of its cell treatment for a disease that causes chronic heart failure. The clinical trial will examine whether Aastrom’s cardiac repair cell technology, delivered through a catheter, can treat dilated cardiomyopathy (DCM). The trial will ...
Ann Arbor-based Aastrom Biosciences Inc. said it is in danger of being removed from the Nasdaq Stock Exchange, Crain's Detroit Business reported. The company said its stock price had remained below the listing threshold of $1. Aastrom produces tissue cell repair and stem cell therapies. Crain's reported that Aastrom will ...
Rise: Timothy Mayleben The former CFO of Esperion Therapeutics - one of the most influential bioscience companies in Ann Arbor’s history - will take over as CEO of Aastrom Biosciences by the end of the year. Aastrom has suffered financial and regulator setbacks, but will now focus on cardiovascular drug ...
A life sciences executive who played a key role in the development of local biotech success Esperion Therapeutics is assuming the top job at an Ann Arbor personalized medicine company, officials announced today. Timothy Mayleben, a founding member of Esperion, will become chief executive officer of Aastrom Biosciences when CEO ...